India Grants Controversial Conditional Approvals To Serum, Bharat COVID-19 Vaccines
Confusion Over Serum's Exports Of AZ Vaccine
India has given conditional accelerated approval to AstraZeneca partner Serum Institute, and separately to Bharat Biotech, for their COVID-19 vaccines. With the latter’s candidate still in Phase III trials, the unprecedented decision has caused controversy given the national regulator had earlier said an EUA would not be granted unless trials are completed.
You may also be interested in...
AstraZeneca is expected to apply for the EU approval of its COVID-19 vaccine next week. The vaccine was developed in partnership with the University of Oxford.
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.
Which vaccines will India use for immunizing its 1.35 billion population against COVID-19? Where will the money come from? Will it allow sales of these vaccines in the market? As the world’s largest democracy gets set to roll out its immunization plan, here’s a look at a few pertinent questions.